Investigating Potential Lawsuits involving NeoStem Inc.
Are you concerned about your investment in NeoStem, Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.
NeoStem, Inc. is a biopharmaceutical company developing novel cell-based individualized medicine therapies, according to a press announcement. The company changed its corporate name to Caladrius Biosciences, Inc., effective June 8, 2015.
According to SEC filings, NeoStem, Inc. filed a Form D to raise capital from investors in 2014. Investments such as these are typically sold by brokerage firms in exchange for a large up front commission. High fees can range from 7-10%, as well as additional “due diligence fees” that can range from 1-3%.
The problem with private placement investments such as NeoStem, Inc. is that they typically involve a high degree of risk. They are also often sold as unregistered securities which lack the same regulatory oversight as more traditional investment products like stocks or bonds.
Securities Investigation – NeoStem Inc.
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk private placements, like NeoStem, Inc. to investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
If you have concerns regarding your investment in NeoStem, Inc. and would like to speak with a securities attorney about your options, please call The White Law Group at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.
For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.
Tags: Caladrius Biosciences, NeoStem Inc., NeoStem Inc. complaints, NeoStem Inc. default, NeoStem Inc. help, NeoStem Inc. high commissions, NeoStem Inc. information, NeoStem Inc. investigation, NeoStem Inc. investment, NeoStem Inc. investment losses, NeoStem Inc. investor relations, NeoStem Inc. investors, NeoStem Inc. losses, NeoStem Inc. ppm, NeoStem Inc. private placement, NeoStem Inc. prospectus, NeoStem Inc. recovery options, NeoStem Inc. risk, NeoStem Inc. stock information, NeoStem Inc. update Last modified: March 15, 2019